Details

Autor(en) / Beteiligte

• Kristen, Arnt V.
• Lehrke, Stephanie
• Buss, Sebastian
• Mereles, Derliz
• Steen, Henning
• Ehlermann, Philipp
• Hardt, Stefan
• Giannitsis, Evangelos
• Schreiner, Rupert
• Haberkorn, Uwe
• Schnabel, Philipp A.
• Linke, Reinhold P.
• Röcken, Christoph
• Wanker, Erich E.
• Dengler, Thomas J.
• Altland, Klaus
• Katus, Hugo A.

Titel

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report

Ist Teil von

• Clinical research in cardiology, 2012-10, Vol.101 (10), p.805-813

Ort / Verlag

Berlin/Heidelberg: Springer-Verlag

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Treatment options in patients with amyloidotic transthyretin (ATTR) cardiomyopathy are limited. Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (GT), inhibits fibril formation from several amyloidogenic proteins in vitro. Thus, it might also halt progression of TTR amyloidosis. This is a single-center observational report on the effects of GT consumption in patients with ATTR cardiomopathy. Methods 19 patients with ATTR cardiomyopathy were evaluated by standard blood tests, echocardiography, and cardiac MRI ( n  = 9) before and after consumption of GT and/or green tea extracts (GTE) for 12 months. Results Five patients were not followed up for reasons of death ( n  = 2), discontinuation of GT/GTE consumption ( n  = 2), and heart transplantation ( n  = 1). After 12 months no increase of left ventricular (LV) wall thickness and LV myocardial mass was observed by echocardiography. In the subgroup of patients evaluated by cardiac MRI a mean decrease of LV myocardial mass (−12.5 %) was detected in all patients. This was accompanied by an increase of mean mitral annular systolic velocity of 9 % in all 14 patients. Total cholesterol (191.9 ± 8.9 vs. 172.7 ± 9.4 mg/dL; p  < 0.01) and LDL cholesterol (105.8 ± 7.6 vs. 89.5 ± 8.0 mg/dL; p  < 0.01) decreased significantly during the observational period. No serious adverse effects were reported by any of the participants. Conclusions Our observation suggests an inhibitory effect of GT and/or GTE on the progression of cardiac amyloidosis. We propose a randomized placebo-controlled investigation to confirm our observation.